整合素α_3β_1在乳腺癌中的表达及其临床意义

Expression of integrinα_3 and integrin β_1 in breast cancer and its clinical significance

目的探讨乳腺癌中整合素α_3、β_1的表达及其生物学意义,并进行临床病理学评估。方法采用免疫组织化学方法,检测32例乳腺癌组织及其癌旁组织中整合素α_3、β_1的表达。结果在非肿瘤乳腺组织中,整合素α_3未检出有阳性表达,整合素β_1的免疫组织化学阳性率为25%(8/32);原发灶癌细胞整合素α_3、β_1的免疫组织化学阳性率分别为36%(12/32)和81%(26/32)。结论整合素α_3、β_1与乳腺癌的生物学行为密切相关,其表达的检测对乳腺癌的浸润程度、转移特性及预后判断有一定临床价值。

Objective To investigate the expression of integrin α3 and integrin β1 in breast cancer and its biological significance. Methods Immunohistochemical assay was used to determine the expression of integrin α3 and integrin β1 in the breast cancer（32 cases）. Results In normal breast tissue,the positive expression rates of integrin α3 and integrin β1 were 0 % and 25 %. In the breast cancer tissue, the positive expression rates of integrin α3 and integrin β1 were 36 % and 81% . Conclusion The integrin α3 and integrin β1 are close associated with the biological significance of breast cancer. To examine its expression is useful to evaluate the aggressive degree, metastatic potential and prognosis in patients with breast cancer.